An interventional study of Acceleromyography (AMG) and Electromyography (EMG) in Neuromuscular Blockade, sponsored by Matias Vested. Completed at 1 site in Denmark. Open to participants aged 6 Months to 2 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Matias Vested · Not applicable, Interventional, and Treatment
The aim of this study is to compare AMG and EMG (Philips IntelliVue NMT module and Senzime TetraGraph) in the objective monitoring of neuromuscular blocking in children between the age of 6 months and 2 years.The monitoring will be done bilaterally either on n.ulnaris or n. tibialis. The hypothesis of the study is that AMG will indicate faster recovery time (time to return to TOF 90%) from neuromuscular block than EMG.
Objective neuromuscular monitoring is strongly recommended when administering neuromuscular blocking agents (NMBA). However, objective neuromuscular monitoring may be challenging, especially in smaller children due to the limited size of their extremities which often are not easily accessible due to issues such as sterile draping and surgical equipment. Consequently, paediatric anaesthesia care providers often experience problems with neuromuscular monitoring.
NMBAs improve intubating conditions and prevent airway injury in children and infants (\<12 months of age). However, both patient age and type of anaesthesia influence onset and duration of action. Infants have shorter onset time of NMBAs compared to older children, and a higher proportion of infants had excellent intubating conditions compared to older children at two minutes after a dose of 0.15 mg/kg cisatracurium. Inhalation anaesthetics prolong recovery from cisatracurium compared to total intravenous anaesthesia and a longer duration of action is seen in infants compared to older children. However, as compared to adults, less profound neuromuscular blockade may be sufficient in children to establish satisfactory intubating conditions.
In children \< 3 years old, a study reported residual neuromuscular blockade (TOF (Train Of Four) ratio \< 0.9) among 8% of the included patients after administration of a single bolus of 0.1 mg/kg cisatracurium, but the actual proportion may have been as high as 20%. To prevent residual neuromuscular block, objective neuromuscular monitoring is recommended. In adults residual neuromuscular block may result in respiratory events (hypoxaemia and airway obstruction), unpleasant symptoms of muscle weakness, prolonged post-anaesthesia care unit stay, and an increased risk of postoperative pulmonary complications.
It is possible to monitor onset time and duration of action of NMBAs with electromyography (EMG) or acceleromyography (AMG) by train-of-four (TOF) stimulation of a peripheral nerve. Typically, the ulnar nerve is stimulated. In smaller children the tibial nerve can be used as an alternative. However, a recent study in adults reports that there may be important differences when comparing EMG and AMG TOF monitoring at the ulnar nerve with EMG detecting recovery of neuromuscular function later than AMG. Only one study in infants has reported that monitoring of neuromuscular function with AMG applied on the first toe may be a suitable alternative when the thumb is inaccessible. One recent study has reported the feasibility of monitoring the depth of neuromuscular block in infants using electromyography. No study has to our knowledge compared AMG to EMG in infants and small children.
The investigators hypothesize that AMG will indicate faster recovery (time to return to TOF 90%) from neuromuscular block than EMG A secondary aim of this study is to investigate agreement between the two monitors using a Bland Altman analysis comparing onset time and recovery from deep to moderate rocuronium-induced neuromuscular block with EMG and AMG.
Matias Vested is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Objective neuromuscular monitoring done on n. tibialis bilaterally
Other: Acceleromyography (AMG) · Other: Electromyography (EMG)
Objective neuromuscular monitoring done on n. ulnaris bilaterally
Other: Acceleromyography (AMG) · Other: Electromyography (EMG)
Philips IntelliVue NMT Module
Senzime TetraGraph
Time from injection of rocuronium until appearance of the first TOF ratio ≥ 90
Duration of action, defined as time from end of injection of rocuronium 0.6 mg/kg (2xED95) until appearance of the first TOF (Train Of Four) ratio ≥ 90% monitored at the tibial or ulnar nerve.
Time frame: 12 Hours
Bland Altman analysis
Agreement between the EMG and AMG monitors using a Bland Altman analysis comparing onset time and recovery from deep to moderate NMB with EMG and AMG
Time frame: Within 12 Hours
TOFC=0
Time to TOF-Count=0
Time frame: Within 1 Hour
TOFR ≥ 0.90
Time to TOFR ≥ 0.90
Time frame: Within 4 Hours
TOFC=2
Time to TOF-Count =2
Time frame: Within 2 Hours
Control TOF
Control TOF ratio (baseline) before administration of rocuronium
Time frame: Within 1 Hour
First PTC
Time to reappearance of the first response of PTC (PTC=1)
Time frame: Within 1 Hour
First TOF=1
Time to reappearance of the first response to TOF (TOFC=1)
Time frame: Within 1 Hour
Final TOFR
Final TOF ratio (defined as the TOF ratio upon conclusion of anesthesia)
Time frame: Within 12 hours
Difference between control and final TOFR
Difference between control and final TOF ratio
Time frame: Within 12 Hours
AMG-TOF ratio when EMG-TOFR ≥ 0.90
AMG-TOF ratio when EMG-TOFR ≥ 0.90
Time frame: Within 12 Hours
EMG-TOF ratio when AMG-TOFR ≥ 0.90
EMG-TOF ratio when AMG-TOFR ≥ 0.90
Time frame: Within 12 Hours
Number of artefacts
Numbers of artefacts defined as appearance of ≥ one twitch with amplitude of ≥ 5% height in a period of ≥ 30 seconds with TOF 0
Time frame: Within 12 Hours
Residual neuromuscular blockade
Signs and symptoms of residual neuromuscular blockade * dysphagia/ swallowing impairment assessed by observing difficulties swallowing (yes/no) or * upper airway obstruction * desaturation defined as more than 2 minutes with spO2 \< 93% * reintubation
Time frame: Within 1 hour postoperatively
Plan to share: No
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Matias Vested